If youre ready to embrace your best self without resorting to endless fruit and veggie diets or relying on empty promises
Kolovrat M, Gojkovic S, Krezic I, Malekinusic D, Vrdoljak B, Kovac KK, et al
doi:10.1093/emboj/18.5.1321
[DOI] [PMC free article] [PubMed] [Google Scholar] 102.Thompson JM, Waldie KE, Wall CR, Murphy R, Mitchell EA
Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]
This approach is often used when oral intake is insufficient or when elevated blood concentrations are desired for therapeutic support, including enhanced antioxidant capacity, support for detoxification pathways, and assistance in managing oxidative stress from environmental exposures or illness
